What the Numbers Tell Us: RSV Prevention Successes and Emerging Questions

In this episode, ‘What the Numbers Tell Us: RSV Prevention Successes and Emerging Questions,’ the expert pharmacists explore the following questions:

1. RSV-associated hospitalizations in infants 0-7 months old from 2024-2025 vs 2018-2020 were reduced by around 30%; in infants 0-2 months old, associated hospitalizations fell by around 50%. What are the implications of these reductions for families, pharmacists, and the broader healthcare system?
2. During the same 2024-2025 RSV season, associated hospitalizations in children aged 8-59 months increased compared to the 2018-2020 seasons. What do you believe is the reason for this increase?

The panelists examined the compelling new data showing a 30% reduction in RSV-associated hospitalizations for infants under 8 months and a striking 50% drop for those under 2 months, directly attributable to the introduction of maternal vaccination and monoclonal antibodies. They explored the profound implications of these reductions, including the prevention of family trauma and anxiety, increased patient curiosity and engagement with pharmacists, and reduced pressure on the healthcare system during the respiratory season. The discussion also addressed the puzzling increase in hospitalizations among children aged 8 to 59 months, hypothesizing that this shift may result from the burden of disease moving to an older, unprotected cohort combined with a particularly severe RSV season. This data-driven conversation highlights both the remarkable success of current prevention strategies and the need for continued vigilance and research as the field evolves.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.